Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06377540 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

StatusRecruiting
PhasePhase 2
Started2024-12-04
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Sep 1, 2026 → Sep 1, 2027
See other at-risk trials from Masonic Cancer Center, University of Minnesota

Amendment history

2026-09-30
Primary completion pushed: 2026-09-01 → 2027-09-01
Completion pushed: 2027-09-01 → 2028-09-01
2026-07-02
Study Status v4
Re-verified, no change to tracked fields
2025-06-27
Study Status, Outcome Measures, Eligibility v3
Eligibility criteria+97 characters
[...] IV on ART Exclusion Criteria: Patients with prior history of any grade 2 or higher autoimmune reaction to PD-1 inhibitors, greaternecessitating thanpermanent discontinuation of the PD-1 inhibitor or equalnecessitating tosystemic grade 3immunosuppressants. Has received prior radiotherapy within 2 weeks of start of [...]
Secondary endpoints5 entries, revised
Rate of Complete MetabolicRadiologic Response Rate
2025-01-02
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-12-01→confirmed 2024-12-04
Study sites0→1
2024-09-09
Study Status v1
Start date2024-08-01→2024-12-01
2024-04-17
Original filing
This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell transplant.
Trial Details
NCT Number NCT06377540
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma
Enrollment 28 participants
Start Date 2024-12-04
Primary Completion 2027-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-29